Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897011 | 0.91 | KCNJ1 (0.42) | KCNJ1HTR2BDRD2SLC6A4SLC6A2 | |
| SCHEMBL2728243 | 0.83 | KCNJ1 (0.37) | KCNJ1SLC6A4DRD1TAAR1HTR2A | |
| SCHEMBL286554 | 0.82 | GID4 (0.38) | KCNJ1HTR2CHTR2BDRD1TAAR1 | |
| SCHEMBL10286951 | 0.82 | KCNJ1 (0.40) | KCNJ1HTR2CHTR2BDRD1TAAR1 | |
| Hydrochloric Acid SCHEMBL2733015 | 0.81 | KCNJ1 (0.39) | KCNJ1HTR2CHTR2BSLC6A4DRD1 | |
| SCHEMBL13028033 | 0.81 | KCNJ1 (0.38) | KCNJ1DRD2DRD1TAAR1 | |
| SCHEMBL297794 | 0.79 | DRD1 (0.43) | DRD2SLC6A4SLC6A2DRD1HTR1D | |
| SCHEMBL2731030 | 0.79 | DRD2 (0.44) | HTR2CHTR2BDRD2CHRM3SLC6A4 | |
| SCHEMBL9683553 | 0.77 | DRD2 (0.47) | HTR2BDRD2DRD1TAAR1HTR2A | |
| SCHEMBL2727926 | 0.77 | SIGMAR1 (0.45) | HTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427444-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018211-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885HTR2C 3295/4885HTR2B 3018/4885 |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885HTR2C 3346/4885HTR2B 3206/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885HTR2C 3346/4885HTR2B 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.